Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2018

View Archived Issues

Tumors, T cells, TFs

DWORF binding dwarfs PLN, helps failing hearts

"Typical" screening method yields novel antifungal drug class

Cytokinetics announces new cardiovascular candidates and updates pipeline progress

Increased risk of migraine in African-American children carrying common variants at 5q33.1

Positive data announced from second phase I study of intranasal betahistine

Podocalyxin as a promising new biomarker in women with polycystic ovary syndrome

Urocortin 3 is involved in the pathophysiology of diabetes

ONO-2910640 shows antidepressant-like effect in animal models of depression

PDT with exendin-IRDye700DX slows tumor growth in GLP-1R-positive tumor models

GeNeuro gives update on pHERV-K antibody program for ALS

Transgene initiates phase I/II trial of TG-6002 in advanced gastrointestinal tumors

Hutchison China MediTech initiates phase I study in China with HMPL-523 for AML

Aslan begins phase I study of ASLAN-004 for atopic dermatitis

Merck & Co. discovers antimycobacterial oxazolidinones

Beijing Jacobio Pharmaceuticals, Jacobio-Alpha Pharmaceuticals patent PTP2C inhibitors

Pseudolysin inhibitors presented by Antabio SAS

Novartis discloses protein atonal homolog 1 activators

New 5-HT2C receptor agonists described by AbbVie

Bristol-Myers Squibb discovers PD-1/PD-L1 interaction inhibitors

Eiger reports phase II data on pegylated interferon lambda in HDV infection

MeiraGTx and Janssen enter gene therapy research collaboration and evaluation agreement

GenSight reports 72-week data from REVERSE phase III trial of GS-010 in LHON

Proteostasis updates status of doublet and triplet cystic fibrosis programs

Phase II study of rozanolixizumab achieves proof of concept in myasthenia gravis

Enanta initiates phase IIa study of EDP-938 in RSV challenge model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...